Small Cap Network Blog

Not surprisingly, March’s retail numbers were soft…for most. Discounters like Wal-Mart (WMT) and Costco (COST) did fine, while discretionary goods saw dampened demand. The futures dropped (pre-market) on the news, though that means little to me any more. Why? I’m still mostly in a ‘bet against the open’ mode. That’s why I’m actually glad stocks ‘opened’ a little higher at 9:30 am EST today.

That said, I’m still sitting on my QQQQ April 47 puts, which I bought at $1.85. They’re now worth about $2.00 - a meager 8% gain, though I guess that’s better than getting poked with a sharp stick.

I’m still in the trade for reasons that become a little more clear with the nearby chart. I’m looking for at least a retest of the 20 day moving average line near $43.15. That will give me a little cushion (and perhaps inspire the bears) for what I really want to happen, which is a move all the way back down to the lower Bollinger band (20 day) at $41.62. At that point my puts would be worth about $5.00…a nice 150%+ win. It ain’t happened yet though.

Other things you need to know about….

I love for my stock picks to go higher; I hate for them to surge to the point where anybody else is scared to step in. We should all be used to that by now, but somehow it’s still frustrating to deal with this fire-and-ice mentality.

I say that to preface you for the chart of Telemig Celular Participacoes (TMB), which we recommended back on February 24th when it was trading at $60.75. The current price of $66.20 represents a 9% gain. The problem is, the stock pick gained 13.5% in the last week and a half. That’s just a pace I don’t see being sustained. (If a candle somehow had three ends, it would be the equivalent to all three burning.) Such a move is just likely to invite a wave of profit-taking.

Plus, the quick move puts the stock just a tad under a long-term resistance line. A slower move would have let that line extend further up and out before it was intercepted.

That’s not to say I’m getting out; it’s still a good pick. I’d just rather get to our target price of $79.20 in a straight line (which is usually faster) than by bobbing up and down. Unfortunately, nobody who’s buying or selling the stock asked me what I want. Be patient and tolerant with TMB.

We recently had a reader ask about our coverage of BioCurex (BOCX). Yes, we’re still following the company, though they’re not at the top of our watchlist.

We mentioned a while back that we knew their project was going to take time, so we were going to give them plenty of it. Since then, Abbott (ABT) has indefinitely backed out of their deal with BioCurex…something of a game-changer. BioCurex is still going to proceed with the development of RECAF, but considering Abbott was such a big deal when they teamed up, I can only wonder what kind of blow this is to the company. They’ve been fairly quiet on the topic, which I don’t interpret as a good sign.

On the other hand, they signed Inverness (IMA) as a licensee not too long ago, so maybe the Abbott news doesn’t matter.

The European Patent Office has given them a patent on RECAF, which gives the company much more negotiation power than a ‘pending’ patent would.

Bottom line…we’re still following BioCurex, for the long haul. We don’t/can’t worry about the day to day stuff, as our interest primarily lies in the strength of their RECAF technology. Licensees and patents won’t change that.

Speaking of biotech, I want to point out CEL-SCI’s (CVM) chart again. We previously looked at its higher lows and persistent attack on the ceiling at 70 cents. Since then, the lows have continued to move higher, and the stock is still knocking on the door at 70 cents. Accumulation has picked up as well.

I don’t quite know why the renewed interest. Phase III starts later in the year, and nothing has happened in the meantime that would spark a rally. However, I’ve also observed countless times how biotech stocks trade about two years into the future. As such, I think CEL-SCI is actually one of the best trading opportunities out there right now.

Are you a subscriber to the Small Cap Network newsletter? If not, you’re missing out on some great trading ideas and exclusive market commentary. To sign up, just go to the top right corner of any page of our website. You’ll be joining thousands of other subscribers who have already benefited from our news and views.

Color me clairvoyant, but I suspected this - or something like it - was around the corner for small cap biotech company BioCurex (BOCX). Like I said in my Top Ten Predictions for 2008 edition, the company’s deafening silence was the tip-off that something big was brewing…they have a real hot and cold streak going with publicity effort. This morning we learned that the rumor of a new RECAF licensee wasn’t just a rumor.

Inverness Medical Innovations (IMA) is RECAF’s newest front man. They’ll be joining Abbott Labs (ABT) as a licensee, and in some ways competing with them. The Inverness deal will let them market all uses of the RECAF technology…the ones very close to being ready, and the ones not even close to being ready. (As a reminder, the ‘quick-test’ cancer screener has already been proto-typed, and is undergoing some final tweaking.)

More importantly, the agreement will not only mean royalty payments once sales start, but some up-front fees and R&D milestone payments are part of the deal too. No word on how much, but any revenue at all would be big for BioCurex - which doesn’t have a revenue-bearing product just yet.

Though I don’t this as an immediate game-changer, the rest of the market does. The stock is up 15% today. I also have to think the 41% improvement on December’s lows of 53 cents is also related to today’s news….just a little preemptively.

In the long run - and assuming RECAF does actually make it to commercialization in some form - this is huge for BioCurex and its shareholders.

Here’s the press release.

Like I said a few days ago (and a few days before that), it looks like something is going on with BioCurex (OTCBB: BOCX). Shares of this small-cap biotech had been up by more than 20% today…the highest levels in weeks. Volume is through the roof. And yet, no news. Based on what we know about this small company and its cancer test research, I’m more and more convinced something big is on the way.

I wish I had something more concrete to say, but I don’t. I just know the 80/20 rule applies to trading as well….80% of stock’s gains are made during 20% of their life. Personally, I think we’re entering one of those 20% scenarios. Where or how it will all come out is still anybody’s guess. But, I’ve seen $1.32 act as resistance on the more recent side of the chart. A move past that could spark a rally to $2.00.

Be prepared for volatility (i.e. stay nimble), but I like our chances here.

We first started to talk about BioCurex (OTCBB: BOCX) and this possibility in an August 16th blog entry, which just so happens to be the pivot point for the entire market. By that time, the stock had already posted a few days worth of solid gains on stronger volume. Since then, we’ve seen some outstanding follow-through. I think this upward thrust may finally be the real deal.

Why? Some of the barriers from before didn’t hold the stock down this time. Namely, BOCX is well above all of its key moving average lines. We haven’t seen this much ’stick-to-it-iveness’ since early 2006 (and even that was a half-hearted move).  The volume behind the rally seems to be growing as well.

Each day that passes with even just an incremental gain, I believe, makes BOCX a little less risky. I already liked it quite a bit, but I think the market is finally warming up to the idea as well - now that there’s something to build on.

The reason for the sudden strength? Ultimately, I think investors are finally realizing BioCurex is actually pretty close to getting their diagnostic research to a monetizable status. The recent press releases have all alluded to it. However, there’s another possible reason that’s been brought up by a couple of our readers.

Keep in mind we’re not commenting on the validity of this rationale, nor are we saying the logic is problem-free. We are, however, laying it all out there - in the interest of letting our readers know the facts as well as the potential rumors that may be influencing BOCX’s trading level.

And the rumor? Some Abbott (NYSE: ABT) employees are scheduled to speak at an ISOBM (International Society for Oncodevelopmental Biology & Medicine) conference in mid-September. Their topic, however, features RECAF - a BioCurex development - and its use in radioimminoassays and chemiluminescent assays. If it rings a bell, it might be because BioCurex went through quite a bit to convert their RECAF-based test into a chemiluminescent-friendly tool….at Abbott’s request.

The assumption is that this bodes well for BioCurex and its RECAF cancer test, suggesting it works, and is finally ready to use.

At the same time, we do want to tell you BioCurex has said nothing to this effect. Then again, they couldn’t if they wanted to. Biotech companies who are presenting something new at such a conference are often prohibited from making a public statement about the presentation (or its purpose) until afterwards.

The risk to the assumption is simple - maybe BioCurex isn’t saying anything just because there’s nothing to say. We do find it curious though. This is an obscure connect-the-dots, yet coincides quite well with when the stock started to move. If there’s nothing to it, a lot of people have been fooled.

Given that BioCurex makes for an outstanding speculative idea even without the ISOBM rumor, I know I’d sure be interested in taking a swing. The chart alone tells me something is brewing.

I know I keep coming back to this name, but, it is what it is. And what it is right now - as far as BioCurex (OTCBB: BOCX) is concerned - seems to be pretty good. 

Just take a look at the chart. After establishing a base around 46 cents in late July and early August, we’ve seen a persistent push….a push big enough to get the stock up to its current level of 63 cents (a 37% move, by the way). The volume behind the gain has been pretty respectable too. And, the last of the main moving average lines I watch, which is the 200 day line in this case, has now been surpassed.

Yet there’s no news to support the effort? Well, I suspect there’s some news brewing - we just haven’t heard it yet. Things like this rarely happen out of nowhere. I feel somebody knows something about something, and at least feels good enough about it to put a few bucks on the table. If that is indeed the case, I think we all at least owe it to ourselves to pay attention….just in case any rumor becomes true.

That being said, I’m not completely behind this chart’s potential just yet. BOCX has handed over a couple of fake-outs in recent months, and I’m not going to take the bait earlier than I have to. However, I will point out this is one of the most promising moves I’ve seen in months.

Aggressive speculators may already be in a position. As for anyone a little more skeptical (which is myself at this point), I think a close above last week’s and today’s high of 65 cents could really wipe away some of the perceived risk.

Either way, it’s well worth watching.

I’ll just take care of three observations in one shot here. Though they’re certainly not the only charts worth watching right now, I think Titan Global’s (OTCBB: TTGL), Stockgroup’s (OTCBB: SWEB), and BioCurex’s (OTCBB: BOCX) charts all deserve a little extra love today.

First up, Titan Global. You all know this one’s been on a rampage for a while, but yesterday’s 20 cent pullback (on a closing basis) was a little bit un-nerving. (Even more un-nerving was the high-to-low span from $1.79 to $1.34 over the prior two days.) However, like the champ I think it is, TTGL has already found a stable footing, and is in positive territory for the day. The 20 day line seems to be the upside catalyst. I think that dip from Wednesday was plenty big enough to flush out any overbought pressures, which means the road is cleared for another bullish leg.

Has anybody else noticed BioCurex shares are perking up again? Volume has been solid as well. That’s not to say it’s looking enticing again - it appears the 50 day line is still acting like a ceiling. However, something has changed here. As we’ve been saying off and on for weeks, I think BOCX is a dark horse that should be monitored continually. The stock has the potential to fly, but I don’t think anybody else believes that. That’s why I like it so much….or will like it when I see some of those walls get knocked down.

Just one day after releasing their earnings, Stockgroup is getting hammered. SWEB shares are back under their 200 day line….a little surprising considering the quarterly results were pretty good. Though I ultimately think this company is the real deal (and will deliver as they’ve described), I don’t know if I’d feel good about buying on this dip. I equate it to trying to catch a falling knife. If you’re in, be smart - don’t get married to any stock. If you’re not in but want in, I think things might get worse before they get better. Maybe we should all use the 200 day line as the yes/no signal.

By the way, on all these charts, the timeframes for the moving averages are 20 (blue), 50 (purple), 100 (red), and 200 (green).

If you’re wondering why BioCurex’s (OTCBB: BOCX)  up 14% (7 cents) on the best ‘up’ volume we’ve seen in a month, here’s why - the company issued some comments today about how their RECAF technology may be utilized to spot cancer specifically for ‘at risk’ individuals.

The basic point being made was simply how the advancement of genetic testing may also propagate the use of the BioCurex/RECAF cancer screener. 

Only recently have biotechnicians developed the ability to test - at the gene level - for genetic makeups that make cancer more likely for an individual. As technology progresses, the frequency and reliability of genetic testing for high-cancer-potential scenarios is apt to rise.

The shortcoming in the genetic testing is that it doesn’t actually indicate cancer has been developed - only a higher potential that it will. BioCurex’s comments were just that as more genetic testing was done in the future, the more cancer screening that could/should be done for known at-risk individuals. Ergo, the cultivation of one biotechnology field could be a springboard for another….screening tests. It just so happens that BioCurex is heavily involved in the screenign industry.  

For more on their comments, click here.

So, is the news worth a 7 cent, or 14%, improvement in the company’s value? Well, it really wasn’t news at all - just an idea. But, it makes sense. There’s no immediate or specific revenue stemming from the potential use of a cancer screening test. However, it does present an interesting opportunity that could bear fruit for BioCurex in the future. That’s worth something as an investor.

As far as short-term traders are concerned, the comment may have sparked a fire for you as well. After finding a floor at 46 cents for a couple of weeks, the stock has been working on a big move higher. Today is largely the culmination of the effort.

Personally I’d like to see all the moving averages cross above before diving in, but some speculators may see enough pep in this move to go ahead and take a calculated risk at current levels. I can’t say I disagree with that strategy either.

You probably already heard it, but in case you didn’t, General Electric (NYSE: GE) has decided not to acquire the diagnostic division of Abbott Laboratories (NYSE: ABT). The $8.1 billion deal was first announced in January, and both companies seemed to imply it was a ‘done’ deal. Looks like it wasn’t though. There are plenty or rumored reasons why the deal fell through, but I doubt we’ll ever really know the true reason.

We wanted to note it here though, as some of you may have questions about where BioCurex (OTCBB: BOCX) will end up landing as a result the news.

You may recall Abbott was going to be a licensee for BioCurex’s RECAF technology, and was even helping them move its development along. With the possible sale of the diagnostics division, any rights and responsibilities Abbott had would be transferred as well. In fact (and incredibly ironically), just a few days ago GE had inked an affirmation of the agreement with BioCurex.

It’s my understanding the GE/BioCurex agreement hinged on the completed sale of Abbott’s diagnostics division. Now with no sale taking place, things should basically be restored to the way they were….meaning Abbott now controls their license again.

Ultimately, I think it’s a non-issue for BioCurex. Both GE and Abbott were supportive of BioCurex’s work, so I don’t know if it even really matters from BioCurex’s perspective. Personally, I’d say it doesn’t.

That being said, there are already whispers of Abbott out there shopping for other potential buyers. As with the GE’s now-undone purchase, I feel any buyer will once again take on any of Abbott’s obligations.

I’ll let you know more when I hear more.

It seems like every few months, RECAF finds yet another use. The latest possibility was announced today. BioCurex (OTCBB: BOCX) believes their RECAF technology may also be used in conjunction with genetic testing for high-cancer-risk individuals, thus expanding the potential size of the market.

Just as a quick recap, BioCurex’s patented RECAF technology was originally put into development as a cancer-detection tool. In fact, early research shows it can be quite successful at doing just that. More recently, the idea of attaching a drug to the RECAF-based marker has been discussed. It would be a powerful possibility, as the marker ‘highlights’ where cancer is, and leaves non-cancerous cells alone. Thus, it may be perfectly-suited to be a drug delivery system. And within the last few weeks, the company announced an effort to develop a ‘point of care’ cancer screening test. Instead of requiring lab work to complete, this test could be performed and fully analyzed with just one doctor’s visit.

Today’s news may have opened yet another door. Whereas a high-cancer-risk individual can be spotted by genetic testing, that same testing doesn’t indicate when cancer has actually been developed. BioCurex’s RECAF test, on the other hand, can do exactly that. By regularly screening these high-risk individuals, the RECAF test may be even more frequently used than first imagined.

Like the press release says, it’s just an idea so far. But, it’s a good one….one that could potentially mean a substantial amount of additional revenue for the company.

Click here for more.

No major surprises with BioCurex (OTCBB: BOCX) today….the stock opened up pretty firmly at $0.60, and has proceeded up to the current level of $0.65. That’s an 8.3% gain so far. Volume has been strong too - 150,000+ shares, and we may see the best volume since early March at the current pace. So, things are going pretty well immediately after we learned General Electric (NYSE: GE) would indeed honor Abbott’s (NYSE: ABT) licensing commitments. 

From here, there is one last thing I’d like to see to really get excited. See the dashed line below? It’s the 200 day moving average line - the grand-daddy of long-term momentum indicators. The reason I’m particularly interested in it right now is BOCX’s recent inability to actually get above it. Even today, touching it seems to have encouraged some profit-taking.

It’s currently at $0.657. Ideally, any current or prospective owners will see a couple of closes above that mark. Being the first close above it since October, that could really carry some weight with any doubters.

Still, the move has already carried the stock past a long-term resistance line red. That’s a good start - I just hope we get some traction this time.

I have to be honest here - I was probably just moments away from throwing in the towel on BioCurex (OTCBB: BOCX). The stock’s been trading really poorly, even with the not-entirely-recent news of possibly using their RECAF cancer marker in an in-office screening test. A couple of days ago we were literally just three cents away from new multi-year lows, and I really didn’t want to be around if things went from bad to worse.

And then….well, the last couple of days have up-ended my less-than-hopeful point of view. Figures.

Now, don’t get me wrong - BioCurex shares have a way of getting wound up and off to a great start, only to stall a few days later. The only point I’m trying to make is to suggest the possibility that BOCX is still in the game….at least from a trading perspective. On the other hand, it’s hardly an encouraging chart.

Take a look. We’ve seen the 50 cent mark tested as support a handful of times over the last three years. At the same time though, we’ve seen those highs get consecutively lower…creating a bearish wedge. If you fear the worst - that the bottom side of the wedge will eventually give way - I don’t think your fears are totally out of line. We’ll burn that bridge when we come to it though. In the meantime, the stock seems to have gotten a reprieve.

On a semi-side note, I think the issue here (one of them anyway) is not knowing what’s going on. The Abbott division BioCurex was working with was the one that was sold, and we learned a few weeks ago how BioCurex’s RECAF technology may have use as a cancer screening test performed at a Doctor’s office. Has nothing material been happening in the meantime? I just have to wonder what’s happening besides that (or even with that). I figured the rest of the market had the same questions, and weren’t tolerating a lack of answers.

Then like clockwork, when things looked darkest, BAM! They bought some time with me, though that’s about it for now.

I’m still a little hesitant to read anything into it though. Maybe if we can get and stay above that resistance line I’d feel a little better.

One possible explanation - could somebody know something and be buying ahead of time? As weak as BOCX is trading, we’ve seen this company issue good news out of nowhere - and drive the stock up in an instant. Maybe this is an early warning, though it’s not a bet I’d be willing to make just yet. 

Though not necessarily our usual ’small cap’ fare, we still think we have to point out something most of the market seems to be missing….a mini-bull market may be starting - or perhaps we should say restarting - in the biotech arena.

The AMEX Biotech Index (BTK) is up 9.5% from lows hit in early March, which easily tops the S&P 500’s 4.5% gain during the same period. On a six-month basis, biotech’s 9.5% rally tops the SPX’s 6.4% gain. Over the last two years, the biotech index is up by 52.9%, versus the S&P 500’s 22.6% run.

The point is, we see a distinct advantage in biotech stocks right now….an advantage we don’t think is likely to go away anytime soon.

So what’s the deal? Is it cyclical? Well, yes and no. It’s cyclical in the sense that biotech can come and go over time, but biotech rarely moves in tandem with the market’s overall bull/bear cycles. However, knowing biotech how we know biotech, it is indeed cyclical….just on a different schedule than almost all other stocks. From that perspective, it looks like a secular bull market for biotech.

In any case, the chart explains why now may be a great time to start looking at this hot spot.

You don’t have to look at this image too long to figure out the bigger trend is to the upside. If you want a piece of the action, we’d say all you really need to do is look for a dip to buy on. Though the index is up well off recent lows, on a macro level, we’re still on the low end of a bullish trading zone….one that’s guiding the index upward.

The reason we’re excited is, once these rallies get started, they’re capable of moving the index 20% to 30% higher, or more.

And for what it’s worth, we don’t think you have to look past our website for a couple of names we feel are worth considering. CEL-SCI (AMEX: CVM) is starting to show us more upside than downside, while BioCurex (OTCBB: BOCX) is looking attractively-priced as well.

And by the way, our track record with biotech picks is pretty darn solid. Aside from making some big gains a few different times with BOCX and CVM, Novelos Therapeutics (OTCBB: NVLT) - which we featured early last year - is up by 50% over the last six months, and seems poised to stay on that roll.

While NVLS may be history, we feel CEL-SCI and BioCurex have the exact same kind of potential, and you may not necessarily have to wait all that long to tap into it. Of course, as always, we think the best time to claim your stake is when nobody else is even thinking about a stock…..kind of like now. In both cases, the companies have demonstrated a legitimate and viable idea in the war on cancer. 

Interesting move here today, in a good way…..BioCurex (OTCBB: BOCX) is up 13% today on major volume, but no news. I suspect there’s more to the story. Or maybe I should say there’s likely to be some underlying story, even though right now there’s no apparent reason for the big move.

The red flag is how today is on track to be at least the second-biggest volume day since February 13th, and that was the day they announced they were working on an in-office cancer screening test. 

One obvious possibility - last week’s marketwise weakness has allowed a second chance for anybody who missed the boat the first time around. The rebound actually began on Friday when 57 cents was hit….which also happened to be the reversal point for January’s slide.

In any case, we think this is something definitely worth noticing. Could it be an omen?

I think I’m getting deja vu here….this is the third time today I’ve made mention of the 20 day moving average line in regards to one of our profiled companies. On the other hand, I’m not surprised about it; under the same overall market scenario, a lot of stocks tend to behave in similar ways.

After reading that, you probably won’t be surprised to read BioCurex (OTCBB: BOCX) shares are finding some nice support at their 20 day line…the kind of smooth, consistent support we like to see.

On February 13th, sailing was anything but smooth. The stock raced from 63 cents a couple of days earlier - on news of a possible cancer screening test - to a high of 77 cents on the 13th. That’s a 22% rally, and while I love gains, those ‘flash’ rallies can really throw a wrench in the works. The rapid run-ups can invite big profit-taking, effectively making a chart difficult to read. The good news is, once the dust settles, we can go on about our business.

In BOCX’s case, now that the volatility is mostly washed away, we can see support being made at a rising 20 day average line. It’s not all-out conclusive evidence of huge gains from here. However, I do think a solid foundation is being laid here. A couple more days of gains could really cement the upward momentum.

BioCurex (OTCBB: BOCX) is up today by 11% today on no news? And up 22.8% from the lows hit in late January. The biggest gains over those ten trading days were also made on slightly higher volume, even though the company has said nothing during that time.

You ever heard the phrase ’stocks talk’? Methinks ’something is up’, in a good way.

If you’re looking for the latest on the progress of BioCurex’s (OTCBB: BOCX) RECAF cancer marker, take the easy route……sit back and watch it on television (or even through the Internet). Gerry Wittenberg, Chairman, will be discussing recent news on RECAF’s development with MoneyTV’s host Donald A. Baillargeon. The nice part is it’s a pretty detailed review, and comes straight from the top.

This episode will be available for a few days if you’d like to watch on the air. Or, if it’s more convenient, you can watch the show online. Links to air times as well as the web-based version can be found here at the MoneyTV.net site.

If you’re looking for the latest on the progress of BioCurex’s (OTCBB: BOCX) RECAF cancer marker, take the easy route……sit back and watch it on television (or even through the Internet). Gerry Wittenberg, Chairman, will be discussing recent news on RECAF’s development with MoneyTV’s host Donald A. Baillargeon. The nice part is it’s a highly detailed review, and comes straight from the top.

This episode will be available for a few days if you’d like to watch on the air. Or, if it’s more convenient, you can watch the show online. Links to air times as well as the web-based version can be found here at the MoneyTV.net site.

While we’d be the first to acknowledge owning BioCurex (OTCBB: BOCX) could have led to sea-sickness since July, we’d also be doing a dis-service if we didn’t mention we think the stock is at the bottom of a widening range right now. It appears yesterday’s 7 cent rally was spurred by a support line that extends all the way back to July. There was one brief instance where shares traded under this line in August, but overall, we feel this is the line to watch if you’re a trader (we think investors may want to pay attention too though, if you’re shopping for an optimal entry spot).

As of right now, that support line is at 66 cents and rising. The resistance line is rising too…at a faster rate. Currently at $1.14, there’s really no way of telling where it might be if and when it’s finally reached again. We’ll keep an eye on it though, and let you know how it shapes up.

In the ultra-short-term, we’ve seen shares top out around 75 cents a few times over the last three weeks. So, we think any potential ‘bigger picture’ move higher within this rising support and resistance framework is going to first depend on getting past that level.

It was only a few days ago, in the October 17th newsletter, we mentioned the importance of viral–marketing top spread the word on a new drug or therapy. The case in point at the time was Biocurex’s (OTCBB: BOCX) RECAF blood test….the cancer-detection test successfully detected stomach cancer in its first known clinical trial for that form of cancer. The results were not surprising, as we’ve seen RECAF test well in the detection of several types of cancer in just the last few months. What we were excited about - for investors - was who did the test, and what they did with the results. The test was performed by an independent team of scientists in Japan, and they wrote about the results in a global medical journal. There are two key benefits here:

1. The fact that an overseas team performed the test at all validates the growing interest in RECAF’s effectiveness
2. The write-up in the industry journal will go far in spreading a credible message about how well RECAF performs

The bottom line for both benefits, though, ultimately means sales for Biocurex - the more people that know about RECAF, and are likely to use it, the bigger the potential market is.

What’s that got to do with Biocurex and RECAF being highlighted television? It’s evidence that publicity is viral…it spreads exponentially once a little momentum is in place. Today we learned RECAF is going to be the topic on an upcoming episode of television’s ‘Your Cancer Today’. This highly-focused show has the potential to introduce a cancer-detection tool to a very interested audience, perhaps continuing to expand knowledge of RECAF, and therefore, expand the market for RECAF.

Maybe the Japanese test was the reason Biocurex will be presented on the television show, or maybe it was Biocurex’s presentation at an industry conference a few weeks ago; we just don’t know. We do know, however, that the buzz is growing - and accelerating.

We encourage you to watch the show, which will be airing this weekend. For local airing times, be sure to visit the program’s website www.YourCancerToday.com.

For the full press release, click here.

Last Wednesday we mentioned Biocurex (OTCBB: BOCX) shares were being re-listed in the NASDAQ’s bulletin board system. Although nothing fundamentally changed about the company and its operations, for shares, getting rid of its pink-sheet status was bound to add an important layer of legitimacy…a crucial characteristic for any stock looking to move to the ‘next level’.

Well, BOCX closed out its last day as a pink sheet stock on Tuesday (the 22nd) at a price of 58 cents. As of right now, the price of 84 cents represents a 44.8% improvement in just four trading days. Like we said then, and as we’ll repeat now, where you’re listed can make all the difference. Fair and logical? Not a chance, but who said this dance makes any sense? All we know right now is that the bulletin board listing has been like night and day compared to its previous pink-sheet listing.

And yes, we still like the company. We’re encouraging investors to start looking for entry points on BOCX shares. One caveat though…the bid/ask data we’re seeing is either (1) non-existent, or (2) showing a ridiculously wide spread. Any bid/ask you see is probably not the actual selling/buying price at that moment. Real-time pricing data is tough to generate for any new listing…since right now, there’s only one market maker. The ‘last trade’ price (real-time or delayed) has been pretty reliable though. The point is, be strict with your entries. Use limit orders, and see if you can actually get some good real-time quotes from your broker (you may have to call) before you take any action. 

Note how Biocurex is trading at new multi-week highs, after breaking above key resistance at the 20-day and 50-day moving averages.

Don’t forget, SmallCap Digest offers free stock ideas and market commentary through our e-newsletter. Be sure to sign up today using the link in the top left corner…and don’t forget to respond to the confirmation e-mail.